金城医药(300233.SZ)公告称，公司全资子公司金城泰尔和金城素智分别收到国家药品监督管理局下发的比索洛尔氨氯地平片和头孢地尼干混悬剂的《药品注册证书》。比索洛尔氨氯地平片为高血压治疗的替代疗法，头孢地尼干混悬剂为口服抗感染药物。这两个产品的获批将进一步丰富公司产品线，并为后续其他产品研发积累经验。然而，药品销售受市场环境等不确定因素影响，投资者需注意风险。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。
金城医药(300233.SZ)公告称，公司全资子公司金城泰尔和金城素智分别收到国家药品监督管理局下发的比索洛尔氨氯地平片和头孢地尼干混悬剂的《药品注册证书》。比索洛尔氨氯地平片为高血压治疗的替代疗法，头孢地尼干混悬剂为口服抗感染药物。这两个产品的获批将进一步丰富公司产品线，并为后续其他产品研发积累经验。然而，药品销售受市场环境等不确定因素影响，投资者需注意风险。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.